Jacksonville local news station, News4Jax, reported TapImmune’s vaccines. Take a look.
Ryan Benk from WJCT had the opportunity to talk with TapImmune President and CEO, Peter Hoang, about our vaccines. Take a look.
TapImmune’s cancer vaccine significantly extended progression free survival of ovarian cancer patients, as compared to the current standard of care.
An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete responses in a Phase 1 trial.
TapImmune released some interesting results this week from a Phase I trial conducted at the Mayo Clinic that will add some spice to that discussion.
TPIV200 vaccine candidate showed 90% of patients developed robust and durable antigen-specific immune responses against FRa.
TapImmune, an immuno-oncology company in Florida is currently clinically testing a vaccine specifically for triple-negative breast and ovarian cancer.
A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer (TNBC).
Precision Vaccination highlighted our cancer vaccine, TPIV200 for treating triple-negative breast cancer.
Peter Hoang, President and CEO of TapImmune, is enthusiastic about a cancer vaccine under development by TapImmune that could help prevent recurrence of such cancers in women.